small molecule multitarget kinase inhibitor bibf-1120 Search Results


co-suspension of nac and nintedanib  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals co-suspension of nac and nintedanib
Inhaling molecules under investigation in pulmonary fibrosis treatment. Smoking, air pollution, and dust represent the main noxae involved in ROS production and inflammation ignited within the lungs. This eventually may lead to a sustained aberrant response of alveolar epithelial cells leading EMT to progress and, finally, to fibrosis and lung parenchyma destruction. Several inhaling molecules are currently under investigation for future employment in pulmonary fibrosis treatment. *: <t>PLGA–nintedanib</t> has currently only been tested in vitro, by Wang et al. . α-SMA: alpha-smooth muscle actin; DMF: dimethyl fumarate; Gal-3: galectin 3; Gly: glycine; EMT: epithelial–mesenchymal transition; HO-1: heme oxygenase 1; Leu: leucine; Lip@VP: Liposome@verteporfin/pirfenidone; LUT@CDMOFs: Luteolin into γ-cyclodextrin metal–organic frameworks; MMP-9: matrix metalloproteinase-9; NAC: N-acetyl cysteine; NF-κB: nuclear factor kappa B; NLRP3: NLR family pyrin domain-containing 3; Nrf2: nuclear factor erythroid factor 2-related factor 2; NS: nanosuspension; PI3Ks: phosphoinositide 3-kinases; PKB: protein kinase B; PLGA: poly lactic-co-glycolic acid; ROS: reactive oxygen species; TD139: thiodigalactoside galectin-3 inhibitor; TGF-β1: transforming growth factor beta 1.
Co Suspension Of Nac And Nintedanib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+molecule+multitarget+kinase+inhibitor+bibf-1120/co+suspension+of+nac+and+nintedanib/pmc11597590-224-20-5
Average 90 stars, based on 1 article reviews
co-suspension of nac and nintedanib - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nintedanib  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals nintedanib
Inhaling molecules under investigation in pulmonary fibrosis treatment. Smoking, air pollution, and dust represent the main noxae involved in ROS production and inflammation ignited within the lungs. This eventually may lead to a sustained aberrant response of alveolar epithelial cells leading EMT to progress and, finally, to fibrosis and lung parenchyma destruction. Several inhaling molecules are currently under investigation for future employment in pulmonary fibrosis treatment. *: <t>PLGA–nintedanib</t> has currently only been tested in vitro, by Wang et al. . α-SMA: alpha-smooth muscle actin; DMF: dimethyl fumarate; Gal-3: galectin 3; Gly: glycine; EMT: epithelial–mesenchymal transition; HO-1: heme oxygenase 1; Leu: leucine; Lip@VP: Liposome@verteporfin/pirfenidone; LUT@CDMOFs: Luteolin into γ-cyclodextrin metal–organic frameworks; MMP-9: matrix metalloproteinase-9; NAC: N-acetyl cysteine; NF-κB: nuclear factor kappa B; NLRP3: NLR family pyrin domain-containing 3; Nrf2: nuclear factor erythroid factor 2-related factor 2; NS: nanosuspension; PI3Ks: phosphoinositide 3-kinases; PKB: protein kinase B; PLGA: poly lactic-co-glycolic acid; ROS: reactive oxygen species; TD139: thiodigalactoside galectin-3 inhibitor; TGF-β1: transforming growth factor beta 1.
Nintedanib, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+molecule+multitarget+kinase+inhibitor+bibf-1120/nintedanib/pmc09405731-72-0-3
Average 90 stars, based on 1 article reviews
nintedanib - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
bevacizumab  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals bevacizumab
Inhaling molecules under investigation in pulmonary fibrosis treatment. Smoking, air pollution, and dust represent the main noxae involved in ROS production and inflammation ignited within the lungs. This eventually may lead to a sustained aberrant response of alveolar epithelial cells leading EMT to progress and, finally, to fibrosis and lung parenchyma destruction. Several inhaling molecules are currently under investigation for future employment in pulmonary fibrosis treatment. *: <t>PLGA–nintedanib</t> has currently only been tested in vitro, by Wang et al. . α-SMA: alpha-smooth muscle actin; DMF: dimethyl fumarate; Gal-3: galectin 3; Gly: glycine; EMT: epithelial–mesenchymal transition; HO-1: heme oxygenase 1; Leu: leucine; Lip@VP: Liposome@verteporfin/pirfenidone; LUT@CDMOFs: Luteolin into γ-cyclodextrin metal–organic frameworks; MMP-9: matrix metalloproteinase-9; NAC: N-acetyl cysteine; NF-κB: nuclear factor kappa B; NLRP3: NLR family pyrin domain-containing 3; Nrf2: nuclear factor erythroid factor 2-related factor 2; NS: nanosuspension; PI3Ks: phosphoinositide 3-kinases; PKB: protein kinase B; PLGA: poly lactic-co-glycolic acid; ROS: reactive oxygen species; TD139: thiodigalactoside galectin-3 inhibitor; TGF-β1: transforming growth factor beta 1.
Bevacizumab, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+molecule+multitarget+kinase+inhibitor+bibf-1120/bevacizumab/pm28649871-198-10-52
Average 90 stars, based on 1 article reviews
bevacizumab - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
nintedanib bibf1120  (MultiTarget Pharmaceuticals)
90
MultiTarget Pharmaceuticals nintedanib bibf1120
Inhaling molecules under investigation in pulmonary fibrosis treatment. Smoking, air pollution, and dust represent the main noxae involved in ROS production and inflammation ignited within the lungs. This eventually may lead to a sustained aberrant response of alveolar epithelial cells leading EMT to progress and, finally, to fibrosis and lung parenchyma destruction. Several inhaling molecules are currently under investigation for future employment in pulmonary fibrosis treatment. *: <t>PLGA–nintedanib</t> has currently only been tested in vitro, by Wang et al. . α-SMA: alpha-smooth muscle actin; DMF: dimethyl fumarate; Gal-3: galectin 3; Gly: glycine; EMT: epithelial–mesenchymal transition; HO-1: heme oxygenase 1; Leu: leucine; Lip@VP: Liposome@verteporfin/pirfenidone; LUT@CDMOFs: Luteolin into γ-cyclodextrin metal–organic frameworks; MMP-9: matrix metalloproteinase-9; NAC: N-acetyl cysteine; NF-κB: nuclear factor kappa B; NLRP3: NLR family pyrin domain-containing 3; Nrf2: nuclear factor erythroid factor 2-related factor 2; NS: nanosuspension; PI3Ks: phosphoinositide 3-kinases; PKB: protein kinase B; PLGA: poly lactic-co-glycolic acid; ROS: reactive oxygen species; TD139: thiodigalactoside galectin-3 inhibitor; TGF-β1: transforming growth factor beta 1.
Nintedanib Bibf1120, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/small+molecule+multitarget+kinase+inhibitor+bibf-1120/bibf1120/pm25959741-160-0-4
Average 90 stars, based on 1 article reviews
nintedanib bibf1120 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Inhaling molecules under investigation in pulmonary fibrosis treatment. Smoking, air pollution, and dust represent the main noxae involved in ROS production and inflammation ignited within the lungs. This eventually may lead to a sustained aberrant response of alveolar epithelial cells leading EMT to progress and, finally, to fibrosis and lung parenchyma destruction. Several inhaling molecules are currently under investigation for future employment in pulmonary fibrosis treatment. *: PLGA–nintedanib has currently only been tested in vitro, by Wang et al. . α-SMA: alpha-smooth muscle actin; DMF: dimethyl fumarate; Gal-3: galectin 3; Gly: glycine; EMT: epithelial–mesenchymal transition; HO-1: heme oxygenase 1; Leu: leucine; Lip@VP: Liposome@verteporfin/pirfenidone; LUT@CDMOFs: Luteolin into γ-cyclodextrin metal–organic frameworks; MMP-9: matrix metalloproteinase-9; NAC: N-acetyl cysteine; NF-κB: nuclear factor kappa B; NLRP3: NLR family pyrin domain-containing 3; Nrf2: nuclear factor erythroid factor 2-related factor 2; NS: nanosuspension; PI3Ks: phosphoinositide 3-kinases; PKB: protein kinase B; PLGA: poly lactic-co-glycolic acid; ROS: reactive oxygen species; TD139: thiodigalactoside galectin-3 inhibitor; TGF-β1: transforming growth factor beta 1.

Journal: Pharmaceutics

Article Title: Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents

doi: 10.3390/pharmaceutics16111391

Figure Lengend Snippet: Inhaling molecules under investigation in pulmonary fibrosis treatment. Smoking, air pollution, and dust represent the main noxae involved in ROS production and inflammation ignited within the lungs. This eventually may lead to a sustained aberrant response of alveolar epithelial cells leading EMT to progress and, finally, to fibrosis and lung parenchyma destruction. Several inhaling molecules are currently under investigation for future employment in pulmonary fibrosis treatment. *: PLGA–nintedanib has currently only been tested in vitro, by Wang et al. . α-SMA: alpha-smooth muscle actin; DMF: dimethyl fumarate; Gal-3: galectin 3; Gly: glycine; EMT: epithelial–mesenchymal transition; HO-1: heme oxygenase 1; Leu: leucine; Lip@VP: Liposome@verteporfin/pirfenidone; LUT@CDMOFs: Luteolin into γ-cyclodextrin metal–organic frameworks; MMP-9: matrix metalloproteinase-9; NAC: N-acetyl cysteine; NF-κB: nuclear factor kappa B; NLRP3: NLR family pyrin domain-containing 3; Nrf2: nuclear factor erythroid factor 2-related factor 2; NS: nanosuspension; PI3Ks: phosphoinositide 3-kinases; PKB: protein kinase B; PLGA: poly lactic-co-glycolic acid; ROS: reactive oxygen species; TD139: thiodigalactoside galectin-3 inhibitor; TGF-β1: transforming growth factor beta 1.

Article Snippet: Conversely, the idea of a multitarget intervention in ILDs has led to the development of the co-suspension of NAC and nintedanib.

Techniques: In Vitro

Pharmacological inhaled agents with antifibrotic properties: in vitro and murine models.

Journal: Pharmaceutics

Article Title: Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents

doi: 10.3390/pharmaceutics16111391

Figure Lengend Snippet: Pharmacological inhaled agents with antifibrotic properties: in vitro and murine models.

Article Snippet: Conversely, the idea of a multitarget intervention in ILDs has led to the development of the co-suspension of NAC and nintedanib.

Techniques: In Vitro, Drug discovery, Cell Culture, Expressing, Suspension, Formulation, Produced, Functional Assay

Inhaled antioxidant agents in pulmonary fibrosis: murine models.

Journal: Pharmaceutics

Article Title: Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents

doi: 10.3390/pharmaceutics16111391

Figure Lengend Snippet: Inhaled antioxidant agents in pulmonary fibrosis: murine models.

Article Snippet: Conversely, the idea of a multitarget intervention in ILDs has led to the development of the co-suspension of NAC and nintedanib.

Techniques: Liposomes, Expressing, Formulation